Preliminary analysis of efficacy and safety of intensity-modulated radiotherapy for stage IVA thymoma

中华放射肿瘤学杂志 Pub Date : 2020-03-15 DOI:10.3760/CMA.J.ISSN.1004-4221.2020.03.006

D. Chang, Ping Li, Jing Li, Yong Wang, J. Cui, Yingjie Wang, T. Xia

{"title":"Preliminary analysis of efficacy and safety of intensity-modulated radiotherapy for stage IVA thymoma","authors":"D. Chang, Ping Li, Jing Li, Yong Wang, J. Cui, Yingjie Wang, T. Xia","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.006","DOIUrl":null,"url":null,"abstract":"Objective \nTo preliminarily evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) in the treatment of inoperable stage ⅣA thymoma. \n \n \nMethods \nA retrospective analysis of 15 patients with inoperable stage ⅣA thymoma receiving IMRT from January 2010 to December 2017 was performed. Among them, 9 patients were male and 6 female, aged 31-83 years with a medianof 59 years. The dose of radiotherapy was 50Gy/60Gy/70Gy/15-20 fractions for PTV/CTV/GTV. The short-term efficacy, overall survival rate and adverse reactions were analyzed. \n \n \nResults \nThe follow-up rate was 100%. The median follow-up time was 48 months. The short-term partial remission rate was 93%(14/15). The 1-, 3-and 5-year overall survival rates were 100%, 75% and 75%, respectively. One patient presented with grade 3 hematological reaction. Four patients died of tumors. \n \n \nConclusion \nPreliminary findings demonstrate that IMRT is an efficacious and safe treatment of stageⅣA thymoma, which can be applied for patients with unresectable thymoma. \n \n \nKey words: \nThymoma/intensity-modulated radiotherapy; Treatment outcome; Safety","PeriodicalId":10288,"journal":{"name":"中华放射肿瘤学杂志","volume":"29 1","pages":"184-186"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To preliminarily evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) in the treatment of inoperable stage ⅣA thymoma. Methods A retrospective analysis of 15 patients with inoperable stage ⅣA thymoma receiving IMRT from January 2010 to December 2017 was performed. Among them, 9 patients were male and 6 female, aged 31-83 years with a medianof 59 years. The dose of radiotherapy was 50Gy/60Gy/70Gy/15-20 fractions for PTV/CTV/GTV. The short-term efficacy, overall survival rate and adverse reactions were analyzed. Results The follow-up rate was 100%. The median follow-up time was 48 months. The short-term partial remission rate was 93%(14/15). The 1-, 3-and 5-year overall survival rates were 100%, 75% and 75%, respectively. One patient presented with grade 3 hematological reaction. Four patients died of tumors. Conclusion Preliminary findings demonstrate that IMRT is an efficacious and safe treatment of stageⅣA thymoma, which can be applied for patients with unresectable thymoma. Key words: Thymoma/intensity-modulated radiotherapy; Treatment outcome; Safety

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

调强放疗治疗IVA期胸腺瘤的疗效和安全性初步分析

目的初步评价调强放疗（IMRT）治疗不能手术的ⅣA期胸腺瘤的疗效和安全性。方法对2010年1月至2017年12月接受IMRT治疗的15例不能手术的ⅣA期胸腺瘤患者进行回顾性分析。其中男性9例，女性6例，年龄31-83岁，中位年龄59岁。PTV/CTV/GTV的放疗剂量为50Gy/60Gy/70Gy/15-20次。分析近期疗效、总生存率及不良反应。结果随访率100%。中位随访时间为48个月。短期部分缓解率为93%（14/15）。1年、3年和5年的总生存率分别为100%、75%和75%。一名患者出现3级血液学反应。4名患者死于肿瘤。结论IMRT治疗ⅣA期胸腺瘤安全有效，可用于不可切除的胸腺瘤患者。关键词：胸腺瘤/调强放疗；治疗结果；安全

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中华放射肿瘤学杂志

自引率

0.00%

发文量

6375

期刊介绍： The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.